TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Child socioemotional development
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maternal psychosocial factors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Distress: Child Self-Report
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Distress: Parent Report
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Distress: Observational Ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline on the Teacher Knowledge Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline on the Classroom Observation of Teachers Skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI BOLD signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Positive visual FBB-PET scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morbidity of patients with Multiple Myeloma
Endpoint domain: Mortality/survival
Primary endpoint: Mortality of patients with Multiple Myeloma
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity and Specificity of Cytological Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of successful CTC culture growths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Valve-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Device-related re-intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 30-day major adverse events (MAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: P(stop) at fasting state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction errors at fasting state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful inhibition at fasting state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech: intelligibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech: velopharyngeal competence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech: articulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported outcomes related to speech and speaking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hearing: puretone average
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental: dmft and DMFT scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder Storage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Three dimensional (3D) change in the maxillary geometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with adverse events/serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Impact of the disease on the patient's daily life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Preference for Combination Therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in Neuropathy Impairment Score (NIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Successful Transition to Oral Treprostinil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral density and content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immune-related best overall response (irBOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Objective Response (OR) in Exploration Cohorts C1A and C1B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in patient treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinicians' experience
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Patients' experience
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: patients' preparedness for surgery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Achievement of Hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: occurrence of severe cardiac arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cardiac arrest or sudden death
Endpoint domain: Mortality/survival
Primary endpoint: Count of patients with collected samples
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Neurocognitive Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in ASIA Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Action Potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of Grade 3-5 Infusional Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Predefined Hemodynamic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Predefined Respiratory Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of any dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Identification of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in weekly frequency of moderate to severe vasomotor symptoms (VMS) from Baseline to Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in weekly frequency of moderate to severe vasomotor symptoms (VMS) from Baseline to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in severity of moderate to severe vasomotor symptoms (VMS) from Baseline to Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in severity of moderate to severe vasomotor symptoms (VMS) from Baseline to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of real-time intraoperative NIR lymphatic mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥2 Point Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cutaneous examination (TCE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carboxyhemoglobin (COHb) levels in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Excretion of 3-hydroxypropyl mercapturic acid (3-HPMA) in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excretion of monohydroxybutenyl mercapturic acid (MHBMA) in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excretion of S-phenyl mercapturic acid (S-PMA) in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ß-Thromboglobulin levels in shed blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Stroke Impact Scale (SIS 3.0)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Modified Rankin Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of sexual desire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in pain responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of aqueous and vitreous inflammatory cells-change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in serum creatinine values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improved erectile dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma HIV-1 RNA change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative levels of 2-hydroxyglutarate (2-HG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Healthcare Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Speech-motor response percent compensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysarthria symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voxel-based morphometry (VBM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: proportion of patients receiving evidence-based interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in prescription of evidence-based treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Miscarriage rate before 8 weeks of gestation
Endpoint domain: Mortality/survival
Primary endpoint: Adverse Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Delta HIV Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Delta Blood CD4 Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Live birth rate (without congenital abnormality or malformation)
Endpoint domain: Mortality/survival
Primary endpoint: occludin level expression in left colonic biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: plasmatic zonulin expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diagnosis of Parkinson Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burns conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of stroke
Endpoint domain: Mortality/survival
Primary endpoint: Reward Positivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severity and frequency of Cold / Flu symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Harmonic measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of reduction in Anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of reduction in Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hamilton Anxiety Rating Scale (HAMA) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in brachial artery flow-mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Organ Sparing Survival
Endpoint domain: Mortality/survival
Primary endpoint: Changes of Score on the Female Sexual Function Index (FSFI)
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Apolipoprotein-B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: oxidized LDL particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasminogen activator inhibitor type 1 (PAI-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: endoscopic healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Motor evoked potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intracortical inhibition & Intracortical facilitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood oxygen dependent level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implicit sequential motor task performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cross-sectional area of muscle fibers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intermyofibrillar mitochondrial content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal calcium-activated tension single muscle fiber tension and shortening velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in plasma phosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: posttraumatic stress disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Retention rate to the art therapy program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to the art therapy program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Participants' acceptability and perceptions of the effects of the art therapy program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in walking arthritis pain intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GM-CSF autoantibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum Amylase Levels at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Tympanic Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of PNH-type cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prostate biopsy Gleason grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Relative Change in Sequence specific parameters for Diffusion tensor imaging (DTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Change in Sequence specific parameters for Diffusion weighted imaging (DWI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Change in Sequence specific parameters for Dynamic contrast enhanced (DCE) MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in heart rate during constant load cycling exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: M7824 related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Target Lesion Primary Patency (TLPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Access Circuit Primary Patency (ACPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of Device and Procedure Related Adverse Events involving the access circuit
Endpoint domain: Adverse events/effects
Primary endpoint: Opioid Tapering Rate, Category 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid Tapering Rate, Category 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid Tapering Rate, Category 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success or failure of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worst Itch Numeric Rating Scale (WI-NRS) Responder Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in craniovertebral angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-Weighted Sum of Pain Relief Rating and Pain Intensity Difference Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking stability indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatial accuracy of walking trajectories
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neural activity measured by fMRI BOLD signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Highest safe dose frequency or maximally planned dose
Endpoint domain: Adverse events/effects
Primary endpoint: Time to dose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colon cleansing level score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of colon capsules excreted over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of cytokines (TNF alpha, IL-6, MIP-2, IL-8, MCP-1, IFN-beta)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Progression Free Survival (PFS) in non-tBRCA HRD positive patients
Endpoint domain: Mortality/survival
Primary endpoint: Progression Free Survival (PFS) in all non-tBRCA patients
Endpoint domain: Mortality/survival
Primary endpoint: Timing of peak antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Long-term variability of hemagglutinin inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Long-term variability of neuraminidase inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in dyspnea intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastro-intestinal tolerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in Partial Seizure Frequency Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fetal Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in signal intensity measured using tDCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in signal intensity measured during EEG recording
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in signal intensity measured during MEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI fibroglandular volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interval before biochemical failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: carbon dioxide production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: respiratory quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: symptoms scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mortality of postoperative acute renal failure
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Suicidal Ideation, Suicidal Behavior, and Self-Injurious Behavior Without Suicidal Intent Based on the Columbia Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Cognition, Using Montreal Cognitive Assessment (MoCA)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Evolution to brain death state within 48 hours
Endpoint domain: Mortality/survival
Primary endpoint: safety profile of procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Change in magnitude of muscle tear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Percentage of Participants With Objective Response (OR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants by Best Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DSM-5 diagnosis of a chronic tic disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival to hospital discharge with neurologic outcome
Endpoint domain: Mortality/survival
Primary endpoint: NRS (Numeric Rating Scale) 4 hours postoperative
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Re-donation rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Perception of HCV Treatment Success
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in employment status
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Maternal Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of infants infected with hepatitis B
Endpoint domain: Adverse events/effects
Primary endpoint: Daily life stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of blood loss of 500 mL or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes